PartnerRe

PartnerRe is delighted to have Ankur Gupta join as CEO India. For more about our risk solutions & to contact us: https://www.partnerre.com/  #reinsurance #insurance

Inwoong Han, Senior Product Development Actuary, and Tae Su (Troy) Kim, Head of Medical Underwriting Solutions, recently shared insights from our latest consumer research into Korea's ageing and caregiving needs at the APAC L&H PULSE event in Seoul. One finding stood out: Korea's ageing challenge is shifting from protection to care. Despite already high insurance penetration, 50% of consumers with caregiving responsibilities show interest in long-term care solutions, highlighting a significant opportunity for insurers to expand their role beyond traditional protection. As people live longer and family care structures evolve, the need for care-focused solutions is becoming increasingly important. Thank you to everyone who joined us. We look forward to continuing the conversation. Emily Wu Ben Lu  Mae Kim  Inwoong Han  Tae Su (Troy) Kim Hengchang Pan  Hyangmi Park  Jinwon Kim

We were proud to celebrate seven of our young professionals at Marsh Rising Professionals’ Forum 2026, connecting with peers from across the re/insurance industry. Under this year’s theme, “Rise to lead. Rise to solve”, the forum brought together industry voices to share insights on geopolitical disruption, emerging risks and innovation, climate change, energy transition and how the next generation of leaders can rise to the occasion. The event concluded with a memorable gala evening, offering a great opportunity to connect and enjoy after braving the heatwave. Thank you to Marsh for hosting such a great event! #MRP2026 #YourReinsurancePartner  Léa Denner Jerez Diego Edeline Rok Krizaj Edward Leger Guillaume S. Grant T. Fatemeh T. Ingrid Gjonaj Fisk Christian Mitterer

Dementia is rising rapidly across APAC, yet insurance solutions still lag behind the long term medical, financial and caregiving realities families face. In our new article, in InsuranceAsia News, we explore why dementia demands a different protection approach—and what it means for insurers. https://lnkd.in/eS7Euj34

PartnerRe is pleased to announce the appointments of Erik Ruettener as Interim Head of Retro and International, Olivia Bishop as Global Cat, CUO and Head of North America and Carlo Casty as Head of Cat Modeling. For more about our risk solutions & to contact us https://lnkd.in/emSqA7b4 #reinsurance #insurance

Insightful perspective from our colleague Marc Dominic Juhnke on the evolving dynamics of aviation insurance, featured by the IUAI in their #BlueSkyThinking series.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for CASGEVY® (exagamglogene autotemcel), making the CRISPR-based gene therapy available to children as young as 2 years of age with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) and transfusion-dependent beta thalassemia (TDT). Casgevy was previously approved for the treatment of patients aged 12 years and older with SCD with recurrent VOCs or TDT. This expansion significantly broadens access to one of the first commercially available gene-editing therapies for these rare inherited blood disorders. PULSE Insights: ✅ Financial Impact: Moderate to High. Total episode can exceed $3M (WAC $2.2M plus 4–6-week+ IP stay). ✅ Expected Utilization: Low initially, but expected to gradually increase as an additional 5,500 children become eligible in the U.S. and more authorized treatment centers gain experience. ✅ PULSE Services: Gene therapy contracting and coordination of the complete gene therapy episode to help optimize outcomes and manage financial risk. Learn more about this FDA approval: https://lnkd.in/eY6DNz2r

The U.S. Food and Drug Administration (FDA) just announced the approval of TREGZI™, the first and only cell therapy for allogeneic transplant in adults with hematological malignancies. This approval reflects the ongoing evolution of cell therapy, with innovation extending beyond disease treatment to improving transplant outcomes. PULSE Insights: ✅ Financial Impact: Moderate as it increases upfront cost of Allogenic Stem Cell Transplant but potentially reduces costly downstream complications such as graft-versus-host disease.  ✅ Expected Utilization: Low initially; likely to grow at experienced transplant centers.  ✅ PULSE Services: Early transplant referral, network optimization, contract placement, and coordination of the transplant episode. Learn more about this therapy and its implications: https://lnkd.in/e-JgTbGM #celltherapy #transplant

Wrapping up part 1 of PartnerRe's 2026 Global Reinsurance Course, we are honored to receive such wonderful feedback! Read what participants are saying about training with our business experts. We look forward to seeing many of you in September for part 2! #YourReinsurancePartner Cindy Bourdiaux Paul Della-Marta Oliver Frase Andreia Gazola Nicolas Georgy Adrien Haegel Martin Jacquot Francesco Masiero Yvonne Neville Alexandre Podvin Vadim Rodiucov Ursula Thalmann

This month’s PULSE Rounds takes a closer look at organ and bone marrow transplants and their growing impact across the healthcare landscape, highlighting why early engagement and proactive transplant contracting are critical to managing financial exposure and supporting better outcomes. Read our article to learn more:  https://lnkd.in/e4ddi957